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Abstract Field cancerization effects as well as isolated
tumor cell foci extending well beyond the invasive tumor
margin have been described previously to account for local
recurrence rates following breast conserving surgery
despite adequate surgical margins and breast radiotherapy.
To look for evidence of possible tumor cell contamination
or field cancerization by genetic effects, a pilot study
(Study 1: 12 sample pairs) followed by a verification study
(Study 2: 20 sample pairs) were performed on DNA
extracted from HER2-positive breast tumors and matching
normal adjacent mammary tissue samples excised 1–3 cm
beyond the invasive tumor margin. High-resolution
molecular inversion probe (MIP) arrays were used to
compare genomic copy number variations, including
increased HER2 gene copies, between the paired samples;
as well, a detailed histologic and immunohistochemical
(IHC) re-evaluation of all Study 2 samples was performed
blinded to the genomic results to characterize the adjacent
normal tissue composition bracketing the DNA-extracted
samples. Overall, 14/32 (44 %) sample pairs from both
studies produced genome-wide evidence of genetic aber-
rations including HER2 copy number gains within the
adjacent normal tissue samples. The observed single-
parental origin of monoallelic HER2 amplicon haplotypes
shared by informative tumor–normal pairs, as well as
commonly gained loci elsewhere on 17q, suggested the
presence of contaminating tumor cells in the genomically
aberrant normal samples. Histologic and IHC analyses
identified occult 25–200 lm tumor cell clusters over-
expressing HER2 scattered in more than half, but not all, of
the genomically aberrant normal samples re-evaluated, but
in none of the genomically normal samples. These genomic
and microscopic findings support the conclusion that tumor
cell contamination rather than genetic field cancerization
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represents the likeliest cause of local clinical recurrence
rates following breast conserving surgery, and mandate
caution in assuming the genomic normalcy of histologi-
cally benign appearing peritumor breast tissue.
Keywords HER2/ERBB2-amplified breast tumors 
Normal adjacent tissue
Introduction
Breast conserving surgery (BCS) is a well-accepted stan-
dard of care for the treatment of both early stage breast
cancer and preinvasive ductal carcinoma in situ (DCIS) [1].
Following initial randomized studies of BCS, efforts were
made by pathologists studying mastectomy specimens to
estimate the amount of occult breast cancer multifocality
and thereby predict the likelihood of recurrence after BCS,
as well as guide the extent of surgical resection margin
needed to remove all invasive tumor cells. Despite initial
reports of multifocality rates as high as 40–60 % [2, 3],
definitions of multifocality restricted to residual tumor foci
outside simulated quadrantectomies led to lower estimates
of 28–38 % [4, 5]. Later mastectomy studies, eliminating
more diffusely spreading invasive phenotypes from con-
sideration (e.g., invasive lobular cancers) and further
restricting primary tumors to those most eligible for BCS
(stages Tis, T1–2), demonstrated that a 2-cm clear surgical
margin would still leave behind occult tumor foci in up to
42 % of cases, a third of which being invasive tumor cell
clusters and the remainder being occult noninvasive foci of
DCIS [6].
Over the [20 years that have elapsed since the com-
pletion of six prospectively randomized trials showing that
BCS followed by whole breast irradiation yielded overall
survival rates comparable to mastectomy, studies of occult
residual tumor burden following BCS have declined
because of the impact of whole breast irradiation in sig-
nificantly reducing but not eliminating potentially life-
threatening loco-regional recurrences, the majority of
which occur near the primary tumor site [7, 8]. However,
technical, cosmetic, and economic issues still beg the
question of how much normal breast tissue should be
removed during BCS to achieve clean surgical margins and
further minimize loco-regional recurrences [7, 8]. More-
over, with BCS, the current standard of care and an ever-
growing need to extract normal host tissue DNA and RNA
from the same small BCS specimen as control samples for
the many high-resolution genetic and epigenetic assays
now being performed on breast tumors [9]; there is
renewed concern about the molecular normalcy of mor-
phologically normal peritumor mammary tissue. Adding
fuel to these clinical and technical questions are several
newly recognized issues: (i) a negative margin of any width
does not indicate the absence of residual occult breast
tumor cells outside that margin [7]; (ii) among BCS eli-
gible patients, the likelihood of multifocality and residual
tumor volume elsewhere in the breast does not correlate
with tumor size [6, 7], but is determined by tumor phe-
notype with triple-negative (ER-negative, PR-negative,
HER2-negative) and HER2-positive breast cancers likeliest
to recur [7, 10]; and (iii) ‘‘field cancerization,’’ character-
ized by genetic and epigenetic alterations in histologically
normal-appearing tissue is common within 5 cm of a breast
tumor margin and thought to provide a microenvironment
conducive to new tumor formation [11, 12].
The term ‘‘field cancerization’’ was coined over
50 years ago [13], but more recently has been redefined to
apply to a morphologically normal-appearing microenvi-
ronment surrounding various tumor types (e.g., breast,
prostate, lung, head and neck, gastrointestinal, and skin
cancers) that, when assayed by high-resolution molecular
assays, exhibits a gradient of genetic and/or epigenetic
aberrancies relative to more remote non-tumor-bearing
areas in that organ [11, 12]. In 1996, Smith and coworkers
[14] first demonstrated genetic loss of heterozygosity
(LOH) in morphologically normal lobules adjacent to most
breast cancers bearing that same LOH; and they postulated
that lost tumor suppressor gene(s) at those loci character-
ized a breast tumor initiating genetic field defect. Later
genetic studies subsequently showed that shortened telo-
meric DNA and four to five times more prevalent LOH loci
characterized the field cancerization of normal-appearing
tissues within 1 cm of microscopically defined tumor
margins [12]. More recently, gene expression profiling of
the peritumor breast microenvironment by different groups
has revealed the presence of two distinct RNA expression
subtypes [15, 16]: one ‘‘normal’’ microenvironment, inde-
pendent of distance from tumor, and another ‘‘active’’
microenvironment, its presence dependent on distance
from the tumor edge and independent of tumor phenotype
yet associated with poorer patient prognosis, and its sig-
nature consistent with extracellular remodeling, wound
healing, fibrosis, and epithelial-to-mesenchymal transition
(EMT) [16]. Whether or not this epigenetic EMT-like
phenotype within histologically normal cancer-adjacent
mammary tissue also reflects any underlying genetic field
cancerization effect remains unclear, as neither of those
two gene expression studies evaluated genomic aberrations
in the microdissected peritumor tissue, and the investiga-
tors concluded that this EMT-like phenotype was a host
reaction unrelated to any specific breast cancer phenotype
[15, 16].
In order to address the questions of residual breast tumor
burden within the peritumor microenvironment and the
genomic status of morphologically normal breast tissue
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surrounding aggressive breast cancers of the same pheno-
type, we performed a pilot study (Study 1, n = 12 cases)
followed by a verification study (Study 2, n = 20 cases) on
DNA samples isolated from HER2-positive breast tumors
(T) and their normal-appearing mammary tissue (N),
excised from 1 to 3 cm beyond the invasive tumor margin.
High-resolution molecular inversion probe (MIP) arrays
(20K array for Study 1, 300K array for Study 2) were used
to examine differences in genome copy number gains and
losses between the T/N pairs; such MIP arrays are capable
of sensitive quantification of allele-specific copy number
changes (ranging from 1 to 60 altered copies per locus)
across the entire genome as well as accurate determination
of allele-specific composition within the HER2 amplicon
[17–20]. We also reasoned that increased HER2 gene
copies would be easier to detect than loss of normal gene
copy numbers arising from occult tumor cells situated
within a field of genomically normal tissue. For correlation
with the 300K MIP array findings in Study 2, a more
detailed microscopic re-evaluation of all N samples was
performed by independent study pathologists blinded to the
genomic data and employing histologic and immunohis-
tochemical (IHC) assays to characterize the adjacent nor-
mal tissue composition bracketing the N sample cores
extracted for DNA. While these retrospective studies pro-
duced microscopic evidence of extratumoral cancer cell
foci in 20 % (4/20) of the N samples from the HER2-
positive cases (Study 2), the 300K MIP arrays detected
excess HER2 gene copy numbers along with other genomic
aberrations consistent with those found in the adjacent
HER2-positive tumors in 35 % (7/20) of the N samples,
along with unrelated genomic aberrations in another 10 %
(2/20) of samples.
Methods
Study samples
Under multi-institutional review board approval, all cryo-
banked (-80 C without fixatives) tissue samples studied
(32 sample pairs, average sample wet weight [100 mg)
were received in two different dry ice batches (Study 1,
archived before 2006; Study 2, archived before 2009) from
the Stiftung Tumorbank Basel with each sample pair coded
and delinked from all personal identifiers. All tumors were
HER2-positive based on a well-validated quantitative
immunoassay for HER2 protein expression performed in
Basel [21], with only the Study 2 samples accompanied by
limited annotation (age-at-diagnosis, ER and PR status,
tumor size, nodal status), as summarized in Table 2, not
including treatment or follow-up data. Swiss pathologists
had microscopically confirmed that all the tumor samples
contained[50 % invasive breast cancer cells, and that the
normal-appearing adjacent mammary tissues had been
excised minimally 1 cm away but no more than 3 cm away
from the invasive tumor margin.
Sample processing for microscopy, DNA extraction,
and MIP microarrays
Cryosectioning was performed on the central core of each
sample (10 sections, 50 lm each) for DNA extraction, with
flanking tissue used to generate at least five 10-lm frozen
section slides for microscopic analysis and correlation with
DNA studies. Frozen sections from the paired tumor and
normal adjacent tissue samples were independently evalu-
ated (blinded to DNA results) by pathologists (AL, FW)
within the Clinical Pathology Laboratory of the University
of California at San Francisco (UCSF) using hematoxylin
and eosin staining (H&E, recording malignant and benign
components including epithelial, fat, stromal, and muscle
cell content) and IHC assay of epithelial HER2 expression
by Hercep Test (DAKO, 0–3 scale), as previously descri-
bed [22]. Core sections were DNA extracted as previously
described for HER2 gene analysis by comparative genomic
hybridization [23], using a standardized UCSF protocol
involving proteinase K digestion, phenol/chloroform/iso-
amyl alcohol (PCI) extraction, and ammonium acetate/
ethanol precipitation followed by TE resuspension and
RNase A digestion (http://waldman.ucsf.edu/protocols/
dna.frozen.htm), and then repeated extraction and precipi-
tation. TE redissolved DNA frozen in 96-well plates
(*200 ng DNA in 50 ll/well) was shipped to Affymetrix,
Inc., Santa Clara, CA (Yuker Wang), where Study 1
sample pairs were analyzed on a 20K MIP array platform
and Study 2 samples were later analyzed on a 300K MIP
array platform, and all pre-processed data returned for
further determination of allele-specific copy number aber-
rations (CNA) [17–20].
Allelic copy number determination, genomic
aberrations, and visualization tools
Pre-processed MIP array data for each sample were ana-
lyzed as previously described [19, 20] after first being
segmented by a modified version of a circular binary seg-
mentation (CBS) algorithm appropriate for single-nucleo-
tide polymorphism (SNP) data [24, 25]. All programming
scripts were performed using R (http://www.rproject.org/).
Inputs into the modified algorithm were the A and B allele
values on the copy number scale for every SNP (after
removing those SNPs with call rate below 90 %). In the
first round of segmentation, square root of the total copy
number (sum of A and B alleles) was used to stabilize the
variance; otherwise, the original copy number scale was
Breast Cancer Res Treat (2012) 136:693–703 695
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used. In the second round, the absolute differences between
the A and B alleles of all heterozygotes were segmented.
The first segmentation was performed with a type I error of
0.009 and the second was performed with a type I error of
0.001, which maintained a typical CBS type I error of 0.01.
Allele-specific means were estimated from the means of
the total copy numbers and means of the differences
between the A and B alleles of the heterozygotes, with the
lower allele-specific mean referred to as the minor copy
number and the upper allele-specific mean referred to as
the major copy number. The minor copy numbers were
combined across adjacent segments if t tests corresponding
to the minimum SNP values were not significant by a
cutoff p value of 0.05. The same was true of the major copy
number and maximum SNP values. Heterozygotes were
identified using an iterative binning method based on the
minimum allele frequency across all SNPs. The bin
between values 0 and 0.25 of size at least 0.05 that con-
tained the lowest ratio of minimum allele values to bin size
was first identified, then any SNP with a minimum allele
value below the bin was estimated to be homozygous,
while any above the bin was estimated to be heterozygous;
SNPs in the bin were estimated to be homozygous or
heterozygous in the same proportion as those outside the
bin, and those with lower values estimated to be hetero-
zygous. Allelic and total copy number differences and
frequencies were analyzed using the Bioconductor R
packages aCGH and DNAcopy [26–28]. For some graphic
purposes, segmentation files were normalized by log2
median centering each sample separately resulting in an
estimated normal copy number at zero, with positive values
indicating an increase in copy number and negative num-
bers indicating a decrease in copy number. Visualization
was also performed with a custom drawing script in python
using the matplotlib visualization library, with data repre-
sented in the box-plot summary view available on the
UCSC Cancer Genomics Browser [29]. Visualization of
the ERBB2/HER2 amplicon on chromosome 17 was per-
formed using the Integrative Genomics Viewer (IGV) [30].
Results
In the pilot study (Study 1), genome-wide allele-specific
copy number analysis was performed using 20K MIP arrays
with 12 paired DNA samples extracted from cryobanked
HER2-positive breast tumor samples and their adjacent
normal tissue, as described in ‘‘Methods’’ section. The
genome-wide total CNA determined from these lower res-
olution MIP arrays are summarized in Fig. 1, showing the
CNA fraction gained or lost for each probe across all 12
tumors (a) and their adjacent normal tissue samples (b). This
study was initially intended to document monoallelic
amplification in breast tumors that had been scored as
HER2-positive prior to archiving by quantitative immuno-
assay [21], and to look for evidence of genomically abnor-
mal peritumor field defects based on earlier evidence of
monoallelic HER2 transcription present in normal-appear-
ing breast epithelium adjacent to HER2-positive tumors
[23]. Individual genomic profiles confirmed the presence of
a 17q12–21 HER2 amplicon in 10/12 (85 %) Study 1
tumors, only half of which appeared to show a monoallelic
haplotype (i.e., single-parental origin). The minimal com-
mon region of this HER2 amplicon haplotype within these
five tumors was *400 kbp in size and consisted of the
following known genes (centromere to telomere direction):
CRKRS, NEURODL, PPP1R1B, STARD3, TCAP, PNMT,
PERLD1, ERBB2/HER2, C17orf37, GRB7, and IKZF3. As
well, all of these HER2-positive tumors appeared genomi-
cally consistent with those described in a larger high-reso-
lution genomic study [31] of HER2-positive breast cancers
by the following criteria: (i) near 40 % frequency of other
chromosome 17q amplification peaks within 17q11–12,
17q21, and 17q23; (ii) [20 % frequency of other chromo-
some copy number gains/amplifications at 1q, 8q, 11q, and
20q loci; and (iii) near 20 % frequency of copy number
losses in other chromosomes at 1p, 8p, 16q, 17p, and 18q
loci. Most strikingly, however, was the detection of HER2
amplification in nearly 60 % of the matched adjacent normal
samples in Study 1 (Fig. 1B), and the finding in 5/12 normals
of the same monoallelic amplicon haplotype as found in
their paired tumor samples. Uncertain whether these Study 1
observations signified the presence in these adjacent tissues
of cancerization with normal-appearing epithelial cells dis-
playing amplified HER2 but few other genomic aberrations,
or the presence of a few contaminating malignant cells ge-
nomically similar to the nearby tumor, we launched Study 2
to verify these findings and better define the histologic nat-
ure of the normal-appearing tissue adjacent to HER2-posi-
tive breast cancers.
Representative histologic (H&E) appearances of a
HER2-positive tumor and a normal-appearing mammary
tissue samples from Study 2 are shown in Fig. 2. Fully
detailed characteristics for each of the 20 Study 2 tumors
(age-at-diagnosis, tumor size and nodal status, ER/PR
status, HER2 receptor expression, and HER2 gene copy
number) are given in Table 1; as well, the corresponding
adjacent normal tissue sample characteristics (histologic,
IHC, MIP) are summarized in Table 2. Importantly, these
HER2-positive tumors appear to be representative of those
found clinically as 75 % were diagnosed at [50 years of
age, half of them lacked hormone receptor expression (ER-
neg, PR-neg), 60 % were node-negative, and 80 % pre-
sented as T1–2 lesions (Table 1). Also shown in Table 1,
all Study 2 tumors contained HER2 amplicons (up to
918 kbp in size, from chromosome 17 positions
696 Breast Cancer Res Treat (2012) 136:693–703
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34179009–35097207) and MIP array estimated HER2 copy
number gains averaging 13.9 allelic copies/tumor and
ranging from as few as 3 to as many as 56.7 copies/tumor,
well within the quantitative dynamic range of the 300K
MIP array platform [17–20]. Despite significant resolution
(probe density) differences in the MIP arrays used in the
two studies, a similar profile of genomic gains and losses
across all chromosomes was apparent between the HER2-
positive tumors in Studies 1 and 2. Likewise, when com-
paring the genome-wide log2 total copy number gains and
losses between the 20 normal and tumor samples (summary
box-plots in Fig. 3A), as seen with the Study 1 sample
pairs, the Study 2 normals showed a striking genome-wide
profile resemblance to the summary tumor profile despite
the difference in their copy number scales (lower copy
number values for normals than tumors), and consistent
with the fact that 11 of the 20 normal samples (# 1, 3, 4, 5,
6, 7, 11, 12, 13, 14, 19) possessed perfectly normal allele-
specific copy numbers across their entire genomes as would
be expected of all genomically normal tissues (Supple-
mentary Fig. 1). Thus, the summary profile of 20 normals
showing allelic copy numbers that vary from 1 (log2 = 0,
p
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Fig. 1 Frequency of significant allelic gain (green) or loss (red)
based on 20K MIP array platform analysis of 12 paired Study 1
samples, plotted as a function of genomic location, with HER2-
positive tumor frequencies shown above (A) and their adjacent
normal breast tissue frequencies shown below (B). The 17q chromo-
some location of the HER2/ERBB2 amplicon is indicated above each
panel. Vertical axis labels indicate fraction of samples with gained
(0 to ?1.0) or lost (0 to -1.0) allelic probes
Fig. 2 Histologic (H&E) images from representative Study 2 cryo-
sections of a HER2-positive cancer (A) and a normal-appearing
cancer-adjacent sample (B). All cancer-adjacent samples were
characterized for constituent histologic elements including fat,
stroma, and epithelium as illustrated above and summarized in
Table 2
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Fig. 3A) reflects the genomic gain and loss contributions
from the aberrant genomes of only 9 of the 20 Study 2
normal samples (# 2, 8, 9, 10, 15, 16, 17, 18, 20), whose
individual sample profiles are shown next to their tumor
sample profiles in Fig. 3B. Of note, there was no statistical
differences in age-at-diagnosis, tumor size, nodal involve-
ment, hormone receptor (ER, PR) status, tumor HER2
expression level or estimated HER2 copy numbers between
sample pairs with or without detectable genomic aberra-
tions in their adjacent normal tissues.
Of the nine normal samples exhibiting some evidence of
genomic aberration (Fig. 3B), only two (# 10, 15) showed
minimal but detectable copy number changes elsewhere
besides the HER2 locus and chromosome 17, suggesting the
absence of contaminating tumor cells and the possible
presence of a field defect or cancerization in these two
samples. Of note, microscopic examination of these normal
samples revealed the presence of only normal-appearing
mammary epithelium in both, with one (#10) showing the
unusual absence of other stromal, fat, or skeletal muscle
components (Table 2) suggesting that its twofold monoall-
elic gain at the telomere of 11p was present in that mor-
phologically normal-appearing mammary epithelium. The
remaining seven normal samples (35 % of Study 2 normals)
showed genomic changes at loci similarly involved by their
matching tumor samples (Fig. 3B), including monoallelic
HER2 copy number gains and a general pattern of 17q, but
not 17p, aberrations similar to their adjacent tumors, as
illustrated in Fig. 4 and consistent with the possibility of
occult tumor cells somewhere within the adjacent normal-
appearing tissue sample. While 60 % of all the normal
samples contained some epithelial components, three of the
seven genomically aberrant normal samples contained nor-
mal stroma and fat but no microscopically detectable benign
or malignant epithelial components (Table 2), suggesting
that the cryosections flanking the larger core sample
extracted for DNA were not adequate to capture contami-
nating tumor cells likely present in the core sample. In
contrast, contaminating tumor cells were confirmed in four
of the seven genomically aberrant normal samples (# 2, 8,
18, 20) which contained occasional 25–200 lm clusters of
malignant, HER2-positive (IHC ?3) cells, as illustrated in
Fig. 5, with or without additional normal-appearing, HER2-
negative (IHC ?1 or ?2) epithelial cells elsewhere in the
same normal sample (Table 2).
Discussion
Long-term (13–20 years) clinical follow-up of randomized
trials of BCS have revealed in breast recurrence rates
ranging from 6 to 20 %, even when negative surgical
Table 1 Summary of Study 2 tumor (T) characteristics including age-at-diagnosis, MIP array estimate of HER2 gene copy number, HER2
protein overexpression level by ELISA, estrogen and progesterone receptor (ER, PR) status, tumor size, stage (T1–4), and nodal (N0–1) status
Sample pair # T # Age T HER2
CN (MIP)
T HER2 U/mg
(ELISA)
T ER T PR T cm Tumor stage Nodal stage
1 21T 50 12.2 659 neg neg 3 2 0
2 22T 57 7 372 pos pos 1.7 1 0
3 23T 39 7.8 362 neg neg 2.5 2 1
4 24T 38 3.8 359 pos neg 2.7 2 0
5 25T 47 5.5 429 pos neg 3 4 1
6 26T 53 17.5 420 neg neg 2.4 2 0
7 27T 78 18 282 pos pos 3 2 1
8 28T 79 4.5 838 neg neg 2.5 2 0
9 29T 46 25.8 430 neg neg 3.5 2 1
10 30T 39 29.9 326 neg neg 2.5 2 1
11 31T 54 5 608 pos neg 4 2 1
12 32T 54 14.1 493 pos pos 1.8 1 0
13 33T 55 18.1 481 neg neg 2.5 2 0
14 34T 54 56.7 814 pos pos 5.5 3 1
15 35T 77 12 446 neg neg 6.2 4 1
16 36T 68 9.8 627 neg neg 2.4 2 0
17 37T 52 18.1 697 neg neg 3 2 0
18 38T 52 3.6 401 pos neg 3 2 0
19 39T 65 4.7 447 pos neg 2.2 2 0
20 40T 67 3 434 pos neg 6 3 0
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margins were as wide as 1–2 cm; these and other studies
have suggested that up to half of such local recurrences
might actually represent new primary cancers arising in
mammary tissue at risk for developing cancer [8]. How-
ever, with most surgeons currently accepting a 2 mm or
less free margin width as sufficient for complete breast
cancer excision [8], such recurrence rates are also consis-
tent with earlier mastectomy studies showing occult tumor
cells commonly residing more than 2 cm beyond the
microscopic tumor edge, potentially capable of invasive
growth and regional spread [6]. We chose to study mor-
phologically normal-appearing mammary tissue adjacent to
HER2-positive breast cancers in part because this aggres-
sive tumor phenotype is molecularly less heterogeneous
than other breast cancer phenotypes yet likeliest to recur
[7, 10], and because an earlier study had suggested that its
adjacent mammary epithelium might be predisposed to
monoallelic HER2 amplification [23]. Therefore, given the
high resolution and sensitivity of MIP arrays, we expected
to find genetic evidence of either field cancerization or
contaminating tumor cells in up to 20 % of normal-
appearing mammary tissue samples excised from 1 to 3 cm
outside the tumor margins of HER2-positive breast can-
cers. Surprisingly, 16/32 (50 %) Study 1 and Study 2
sample pairs produced some evidence of genomic aberra-
tion within the adjacent normal tissue samples with 14/32
(44 %) of these showing significant copy number gains at
the HER2 locus.
The observed single-parental origin of monoallelic
amplicon haplotypes shared by informative tumor–normal
sample pairs, as well as the commonly gained loci else-
where on 17q in adjacent normal samples concordant with
characteristic 17q gains previously described in HER2-
positive breast tumors [31], provided compelling support
for a preliminary conclusion that contaminating tumor cells
probably explained the observed genomic aberrations in
these HER2-positive cancer-adjacent normal samples. On
the other hand, two sample pairs in Study 2 contained
aberrations in their normal tissues that did not mirror their
adjacent tumor genomes, suggesting possible field canc-
erization effects [11, 12], although such genetic field
effects have not been described previously in association
with HER2-positive breast cancers. Therefore, additional
microscopic study of the multiple frozen sections flanking
the DNA-extracted core normal samples from Study 2,
blinded to the genomic results, was considered essential for
histologic insight into the source of the observed genomic
aberrations, understanding that absent microscopic evidence
Table 2 Summary of Study 2 adjacent normal (N) breast tissue
constituents including fat, muscle, and either benign (normal or usual
ductal hyperplasia, UDH) or malignant epithelium, as well as MIP
array determined copy number normalcy or abnormality (CNA) and
HER2 copy number gain and HER2 IHC assay (1–3?) of cancer (CA)
cells identified in the N samples
Sample
pair #
N # N stroma
(yes = 1)
N fat
(yes = 1)
N muscle
(yes = 1)
N epi
(yes = 1)
N epi-
UDH
(yes = 1)
N CA-epi
(yes = 1)
N CA-epi
HER2
(IHC)
N HER2
Gain (MIP,
yes = 1)
N Other
CNA (MIP,
yes = 1)
N normal
CN (MIP,
yes = 1)
1 21N 1 1 1 0 0 0 0 0 1
2 22N 1 1 0 0 0 1 3 1 1 0
3 23N 0 1 0 0 0 0 0 0 1
4 24N 1 1 0 0 0 0 0 0 1
5 25N 1 1 0 0 0 0 0 0 1
6 26N 1 1 0 1 1 0 0 0 1
7 27N 1 1 0 1 1 0 0 0 1
8 28N 1 1 0 0 0 1 3 1 1 0
9 29N 1 1 0 0 0 0 1 1 0
10 30N 0 0 0 1 0 0 0 1 0
11 31N 1 1 0 1 0 0 0 0 1
12 32N 1 1 0 1 0 0 0 0 1
13 33N 1 1 0 1 1 0 0 0 1
14 34N 1 1 0 1 0 0 0 0 1
15 35N 1 1 0 1 0 0 0 1 0
16 36N 1 1 0 0 0 0 1 1 0
17 37N 1 1 0 0 0 0 1 0 0
18 38N 0 1 0 0 0 1 3 1 1 0
19 39N 1 1 0 1 0 0 0 0 1
20 40N 1 1 0 1 0 1 3 1 1 0
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of contaminating tumor cells in these sections would not
constitute proof of tumor cell absence in the larger DNA-
extracted core samples. Indeed, upon histologic and
genomic correlation, 4/7 normal samples with MIP array
evidence of amplified HER2 gene copies also demonstrated
isolated microscopic clusters of HER2-positive cancer cells
easily missed depending on the number of frozen sections
cut and evaluated. Sections flanking the other 3/7 normal
samples showing obvious genomic aberrations and
increased HER2 gene copies revealed normal mammary fat
and stromal elements but no evidence of benign or
malignant epithelium, leading to the presumption that
occult tumor cell foci must have been confined to the larger
DNA-extracted core sample. Importantly, of the 11
adjacent samples with entirely normal genomic profiles, 7
showed normal epithelial elements and 3 of these also
contained some usual ductal hyperplasia (UDH), indicating
that their normal genomic profiles were not likely false-
negative findings due to the absence of adjacent breast
epithelium. Notably, those three normals with UDH did not
show any evidence of either increased HER2 gene copy
number or HER2 overexpression by IHC (Table 2), sug-
gesting that the UDH did not represent precursor lesions
related to the adjacent HER2-positive invasive tumors.
Finally, sections from the two normal samples with aber-
rant genomes but lacking increased HER2 gene copy
numbers and appearing genomically dissimilar to their
matching tumors, contained histologically normal epithe-
lial elements, consistent with prior reports of field canc-
erization occurring in microscopically normal-appearing
breast epithelium [11, 12, 14–16].
In sum, these findings suggest that using high-resolution
genomic profiling, genetic aberrations commonly exist
within morphologically normal breast tissue located well
beyond what is commonly considered a clear surgical
margin for BCS even for aggressive HER2-positive breast
cancers, although the majority (55 %) of our Study 2
sample pairs revealed histologically and genetically normal
tissue adjacent to the HER2-positive tumors. The genomic
profiles and histologic study of our aberrant normal sam-
ples support the conclusion that tumor cell contamination
rather than genetic field cancerization represents the
Fig. 4 IGV display comparing Study 2 chromosome 17 gains/losses
and HER2/ERBB2 amplicon gains in the 7 T/N sample pairs for which
increased 17q and HER2 copy numbers were seen the N samples (top
heatmap panel), and the 2 other sample pairs in which the N samples
showed normal chromosome 17 copy numbers but aberrant genomes
elsewhere (bottom heatmap panel). Heatmaps show segmented
overall copy number variations with red intensities indicating regions
of copy number gain, blue intensities indicating regions of copy
number loss, and white indicating no copy number change. The
HER2/ERBB2 locus is indicated by the red rectangle on the ideogram
(*35 mb)
Fig. 3 Total and allele-specific copy number variations based on
300K MIP array platform analysis of paired Study 2 samples, plotted
as a function of genomic location. A Summary box-plot of log2 copy
number variations across all 20 normal samples and their matching 20
tumor samples. Red (increased copy number) and blue (decreased
copy number) vertical lines indicate upper and lower quantile
variations, colored by their median value; note different copy number
scales for normal (-0.4 to ?0.6) and tumor (-2 to ?3) samples.
Black dots indicate median values across all samples. B Genome-wide
allele-specific copy number comparisons for the 9 HER2-positive
tumor (T)–normal (N) sample pairs in which there was some genomic
aberration detectable in the N sample, with 7 of these showing
17q12–21 HER2 copy number gains (# 2, 8, 9, 16, 17, 18, 20). Major
(yellow) and minor (blue) allelic changes (scaled from 0 to 8 for all
samples) are shown with estimated copy numbers [1.5 considered
significant gains
b
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likeliest explanation for clinically observed local recur-
rence rates up to 20 % following BCS despite post-oper-
ative breast radiotherapy. The observed frequency of
genomically aberrant adjacent normal tissue in our two
studies was consistent with earlier mastectomy studies
showing frequent presence of isolated malignant cells well
beyond tumor margins; and, as with many of these clinical
studies, we found no correlation between our aberrant
adjacent tissue genomic findings with other clinical char-
acteristics of these HER2-positive tumors including age-at-
diagnosis, size, nodal involvement, or hormone receptor
expression. Importantly, this study did not address possibly
common epigenetic field cancerization effects conducive to
de novo tumorigenesis that would require DNA methyla-
tion, microRNA, and mRNA profiling for full character-
ization. As well, despite many recent molecular genetic
approaches, there remain significant statistical challenges
in trying to demonstrate the clonal relatedness of tumors
arising in the same patient at distant sites or at different
points in time [32–34]; therefore, even ignoring the tech-
nical limitation of characterizing minimal tumor DNA
within a pool of normal germline DNA, we cannot abso-
lutely conclude that the genomic aberrancies in our normal
tissue samples equate to contaminating tumor cells derived
from the adjacent primary tumors. In the future, it is
possible that deep exome or whole genome sequencing of
adjacent normal tissue samples will be able to better detect
and differentiate genomic aberrations such as cancer-driv-
ing versus precursor mutations; and such studies are now
underway within The Cancer Genome Analysis (TCGA)
network [9]. The TCGA program, in particular, recognizes
the growing need to employ surgically accessible normal
organ tissues for in depth and accurate genomic profiling of
breast and other cancers; and the present comparison of
HER2-positive tumor and normal sample pairs indicates
that great caution is needed in assuming the genomic
normalcy of histologically benign appearing tissue within
1–3 cm of the invasive tumor margin.
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Fig. 5 Histologic (H&E) and IHC (?3 HER2 overexpression) images of scattered, occult tumor cell clusters (25–200 l) identified in four
HER2-positive cancer-adjacent normal samples (# 2N, 8N, 18N, 20N)
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